Navigation Links
Victhom announces completion of joint venture agreement with Otto Bock for Neurobionix activities
Date:6/18/2009

QUEBEC, June 18 /PRNewswire-FirstCall/ - Following the announcement on April 30, 2009, of the execution of a partnership agreement between Victhom Human Bionics Inc. ("Victhom", TSX: VHB) and Otto Bock HealthCare GmbH ("Otto Bock"), Victhom announced today the completion of the transaction contemplated by the partnership agreement and the approval by its shareholders and debenture holders of the concurrent restructuring of its outstanding convertible debentures by way of plan of arrangement.

On June 16, 2009, the arrangement resolution was approved by 98% of Victhom's shareholders present or represented by proxy at the annual and special meeting of shareholders, and by 97% of the debenture holders at the debenture holders' meeting held earlier that day.

On June 17, 2009, the Quebec Superior Court issued its final order approving the implementation of the plan of arrangement providing inter alia for the consolidation of Victhom's common shares on a 10 for 1 basis and the conversion the 7% convertible debentures maturing in March 2010 in the capital amount of CAN$ 18,354,000 into a newly created class of preferred shares.

The 10:1 consolidation will take effect as of today but the common shares of the Corporation will transact on a post-consolidation basis on the Toronto Stock Exchange on June 23, 2009. It is expected that share certificates representing the preferred shares and the newly consolidated common shares will be made available to debenture holders and shareholders shortly.

As part of the arrangement and pursuant to the partnership agreement, Victhom has transferred all of the assets and liabilities of its Neurobionix division to the newly created general partnership, "Neurostream Technologies General Partnership" ("Neurostream Technologies"), concurrent with an initial equity investment of CAN$ 12.5 million in Neurostream Technologies by Otto Bock. At closing, Neurostream Technologies is owned 55.6% by Otto Bock and 44
'/>"/>

SOURCE VICTHOM HUMAN BIONICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Victhom and Otto Bock sign partnership agreement to establish joint venture for Neurobionix activities
2. Victhom announces the filing of a patent application to address sudden unexplained death in epilepsy (SUDEP)
3. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
4. Victhom Human Bionics Neurobionix Division receives ISO 13485:2003 Certification for its Design Control System
5. Victhom announces the completion of the second phase of the apnea therapy development
6. Victhom Announces Launch of Enhanced Company Website
7. Victhom to Participate in the OneMedPlace Finance Forum
8. Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system
9. Environmental Tectonics Corporation Announces Additional Hyperbaric Monoplace Chamber Sale to St. John Wound Center
10. Shamir Optical Industry Ltd. Announces Availability of Its Annual Report on Form 20-F Through Its Website
11. Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 Today, TiFiber, Inc. ... production facility and future company headquarters in Fort ... new materials that safely and effectively control dangerous ... of its historic, strong support for manufacturing, but ... leading edge, technology-based companies such as TiFiber. ...
(Date:12/19/2014)... Biddeford, ME (PRWEB) December 18, 2014 ... founding director of the Center for Excellence in the ... of New England, has been selected as a member ... He is the first neuroscientist from Maine to receive ... a nonprofit organization supported entirely by the Dana Foundation. ...
(Date:12/19/2014)... (PRWEB) December 18, 2014 iLab Solutions, ... the appointment of Siri Bryant as the new Director ... Director of Core Implementations. These two new leadership positions ... customer service by ensuring that iLab continues to meet ... the last four years, iLab has been deployed at ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 The ... to the rising ageing population and technological innovations ... and nutraceutical industries are catalysing the growth of ... @ http://www.marketsandmarkets.com/Market-Reports/empty-capsules-market-218018190.html , Scope of Report ... as well as new entrants/smaller firms to gauge ...
Breaking Biology Technology:Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4
... (Nasdaq: VRNM ), a pioneer in the ... that it has renewed and extended its joint marketing ... heat transfer, separation and fluid handling technologies, for Purifine® ... agreement to jointly market enzymatic degumming of vegetable oils ...
... SEATTLE, Oct. 26 On Thursday, October ... Central European/5:30 a.m. Pacific, members of Cell ... management team will host a conference call ... financial results.Conference Call NumbersThursday, October 288:30 a.m. ...
... Tengion, Inc. (Nasdaq: TNGN ), a ... Saturday, October 23, 2010 in a podium presentation ... Exchange in Orlando, FL. The presentation highlighted new ... demonstrating promising improvements in kidney function with an ...
Cached Biology Technology:Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement 2Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement 3Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement 4Tengion Presents New Large Animal Data Demonstrating Functional Kidney Regeneration at the American Society for Transplantation Annual Conference 2Tengion Presents New Large Animal Data Demonstrating Functional Kidney Regeneration at the American Society for Transplantation Annual Conference 3Tengion Presents New Large Animal Data Demonstrating Functional Kidney Regeneration at the American Society for Transplantation Annual Conference 4
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , ... for the post-password and Internet of Things era, today ... funding. The venture round was led by Metamorphic Ventures ... Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has raised ... funding to expand its team and bring LaunchKey to ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... addition of the "Global Chemical Sensor Market ... http://photos.prnewswire.com/prnh/20130307/600769 One ... increasing demand for medical sensors in biomedical applications. ... for quick and correct diagnosis during surgical procedures. ...
(Date:12/11/2014)... -- That blood pressure plays a role in human health has ... term for high blood pressure – was first described as ... that,s used in measuring blood pressure was invented in 1896. ... hypertension, its triggers and its effects. In fact, recent findings ... best ways to treat it. For example, a ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... , Sept. 18, 2013 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p01623686/Emerging-Opportunities-in-Global-Biometrics-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Security_Systems ... Manifold,This study analyzes the emerging applications in ...
...  GenesisSolutions (An ABS Group Company), a Fully Integrated Global ... Sciences EAM Symposium for Engineering, Maintenance & Reliability professionals ... in Cary, North Carolina . ... provide participants with examples of Asset Management Best Practices ...
... study led by researchers at Children,s National Medical Center ... promise for the treatment of Duchenne muscular dystrophy (DMD). ... , show that the drug, VBP15, decreases inflammation ... effects linked to current treatments with glucocorticoids such as ...
Cached Biology News:Emerging Opportunities in Global Biometrics Market 2Emerging Opportunities in Global Biometrics Market 3Emerging Opportunities in Global Biometrics Market 4Emerging Opportunities in Global Biometrics Market 5Life Sciences EAM Symposium 2Life Sciences EAM Symposium 3New muscular dystrophy treatment shows promise in early study led by Children's National 2
HSD17B3 Immunogen: HSD17B3 (NP_000188, 29 a.a. ~ 120 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rad51, N-terminal...
Phospho-mu-Opioid Receptor (Ser375) Antibody...
Rabbit polyclonal to WWOX8 ( Abpromise for all tested applications). entrezGeneID: 51741 SwissProtID: Q9NZC7-8...
Biology Products: